AMYLYX PHARMACEUTICALS INC

George Milne’s October 5 sale of 30,000 Amylyx shares at $27.70 shows routine insider profit‑taking amid a 19% yearly rise, indicating stable confidence in the ALS biotech’s pipeline.

Insider buying spree at Amylyx Pharma shows CEO Klee’s confidence in avexitide’s NDA success, hinting at a short‑term rally for investors.

Insightful guide on Amylyx CFO’s March 2 tax‑withholding sale – why it’s routine, not a warning, and what it means for the stock’s bullish outlook.

Insightful look at Amylyx’s insider sales: Mazzariello’s tax‑withholding trades, their impact on stock, and what they reveal about the company’s future.

Insightful look at Amylyx CEO insider sales, tax‑triggers, and what they mean for investors amid ALS drug development uncertainty.